A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's disease

Authors

• Douglas Galasko, University of California - San Diego
• Martin R Farlow, Indiana University
• Brendan P Lucey, Washington University School of Medicine in St. Louis
• Lawrence S Honig, Columbia University
• Donald Elbert, University of Washington
• Randall Bateman, Washington University School of Medicine in St. Louis
• Jeremiah Momper, University of California - San Diego
• Ronald G Thomas, University of California - San Diego
• Robert A Rissman, University of California - San Diego
• Judy Pa, University of California - San Diego
• Vahan Aslanyan, University of Southern California
• Archana Balasubramanian, University of California - San Diego
• Tim West, C2N Diagnostics
• Maria Maccecchini, Annovis Bio
• Howard H Feldman, University of California - San Diego

Journal

Alzheimer's Research & Therapy

Publication Date

7-5-2024

Volume

16

Issue

1

First Page

151

Document Type

Open Access Publication

DOI

10.1186/s13195-024-01490-z

Rights and Permissions

Galasko, D., Farlow, M.R., Lucey, B.P. et al. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alz Res Therapy 16, 151 (2024). https://doi.org/10.1186/s13195-024-01490-z This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Recommended Citation

Galasko, Douglas; Farlow, Martin R; Lucey, Brendan P; Honig, Lawrence S; Elbert, Donald; Bateman, Randall; Momper, Jeremiah; Thomas, Ronald G; Rissman, Robert A; Pa, Judy; Aslanyan, Vahan; Balasubramanian, Archana; West, Tim; Maccecchini, Maria; and Feldman, Howard H, "A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's disease." Alzheimer's Research & Therapy. 16, 1. 151 (2024).
https://digitalcommons.wustl.edu/oa_4/6702

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.